Encompass Health (EHC)
Health Care · inpatient rehabilitation services · NYSE
Encompass Health is the nation’s leading provider of inpatient rehabilitation services, focused on improving patient outcomes through specialized, evidence-based care for complex neurological and physical recovery.
What Encompass Health does
Encompass Health is the largest owner and operator of inpatient rehabilitation hospitals in the United States, providing specialized rehabilitative treatment for patients recovering from major injuries or illnesses, such as strokes and hip fractures. The company utilizes interdisciplinary clinical teams to deliver intensive, facility-based therapy aimed at restoring patient functional ability and independence. Its operations are heavily integrated with the Medicare program and acute-care hospital referral networks across 39 states and Puerto Rico.
Themes: post-acute care, aging demographics, stroke recovery, value-based care, hospital infrastructure
Fundamentals
- Price$120.31 as of 2026-08-21 close
- Market cap$11.9B as of 2026-08-21
- 1-year return-2.5% 2025-08-21 close $123.43 → 2026-08-21 close $120.31
- P/E20.02 as of 2026-08-24
- Net margin+10.0% as of 2026-08-24
- Gross margin+95.8% as of 2026-08-24
- ROE+25.4% as of 2026-08-24
- Debt / equity1.02 as of 2026-08-24
- Revenue growth (YoY)+10.1% as of 2026-08-24
- Revenue CAGR (3y)+10.9% SEC XBRL
- Beta0.76 as of 2026-08-24
- Last reported earnings2026-08-05 SEC EDGAR Form 8-K (Item 2.02)
Dividend: yield +0.9%; 3-year non-decreasing per-share dividend streak (SEC XBRL).
How EHC compares in its sector
- price-to-earnings ratiomiddle range 203 covered Health Care peers, as of 2026-08-24
- net profit margintop 25% 504 covered Health Care peers, as of 2026-08-24
- operating margintop 25% 504 covered Health Care peers, as of 2026-08-24
- gross margintop 10% 384 covered Health Care peers, as of 2026-08-24
- return on equitytop 25% 576 covered Health Care peers, as of 2026-08-24
- 3-year revenue CAGRmiddle range 402 covered Health Care peers
- indicated dividend yieldmiddle range 71 covered Health Care peers, as of 2026-08-24
- free cash flow (absolute dollars, latest fiscal year)top 25% 493 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Top 10 scores & list membership
EHC is in the Health Care Short-term Top 10.
Health Care Short-term Top 10 — since 18 Aug 2026
Long-term score
54.8 #330 of 987 scored · #18 of 57 in Health Care
Growth 70th (3-year revenue CAGR 10.9%, revenue growth year over year 10.1%) and profitability 65th (return on equity 25.4%, operating margin 17.9%); weakest is capital return (28th, consecutive years of dividend increases 3 years).
Short-term score
57.8 #328 of 1,704 scored · #64 of 240 in Health Care
Catalysts 65th: analysts have raised their average price target by 0.9% since the prior reading; volume and participation 65th: it gapped 12.5% above the previous close and has not traded back through the level it left behind — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed; weakest is setup 43rd: day-to-day price swings are unusually wide versus its own recent history (wider than about 84% of the past ~6 months).
In this list since 18 Aug 2026 — currently 8th in the list (3 days)
- Entered 18 Aug 2026: first selection for this list at rank 4, score 67.7.
Scores as of 21 Aug 2026. Each bar is a percentile: how this company ranked against every company the score ranked, 0–100. A list is a published formula and its output, not a recommendation. Method version 2.
Dividend coverage (FY2025)
Covered by reported results. In FY2025, EHC's dividend was covered by reported results (earnings payout 13%, free-cash-flow payout 16%). This describes past coverage, not a forecast.
- Earnings payout13% dividends / net income
- Free-cash-flow payout16% dividends / (operating cash flow − capex)
Coverage derived from reported SEC EDGAR XBRL figures for FY2025 (dividends paid vs. net income and free cash flow, same fiscal year). This describes PAST coverage for one fiscal year — it does not predict whether a dividend will be maintained, raised, or cut, and a one-year payout ratio can be distorted by non-recurring items. Informational only — not financial advice.
How Encompass Health looks technically
Encompass Health (EHC) is trading 12.2% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 10 trading days ago — a "golden cross", a bullish long-term signal. A strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 28, with buyers in control. Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 58, neither overbought (above 70) nor oversold (below 30). MACD, a trend-momentum gauge, turned bearish about 3 trading days ago (its momentum flipped negative). It made a new 20-day high about 10 trading days ago.
Trend
9
| Distance from the 200-day | it is trading 12.2% above its 200-day average, the long-term trend line — a longer-term uptrend | +12.2% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $111.09 | $111.09 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $107.25 | $107.25 |
| Swing structure | each recent peak has been higher than the one before it and each dip has been shallower — the pattern chart-watchers call an uptrend, which describes where price has already been and not where it goes next | higher highs and higher lows |
| Last swing turn | its last significant turn was a swing high 10 calendar days ago — the swings before that are what the structure reading is measured on | 10 sessions |
| Wave structure | its recent swings can be read as a completed three-part upward correction — a pullback in the A-B-C shape Elliott-wave chartists use; the labelling fails if price closes above 127.5. It is one of several labellings that fit, and it describes the swings already printed, not what comes next. The same swings also read as a five-part sequence in leg 4. | possible three-wave upward correction, complete (one of several readings) |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 10 trading days ago — a "golden cross", a bullish long-term signal | 10 sessions |
| Above the 200-day after a dip | it recently dipped to its 200-day average (the long-term trend line) and has since climbed back above it — now about 12.2% above | +12.2% |
| Trend strength (14-day ADX) | a strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 28, with buyers in control | 28.2 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 58, neither overbought (above 70) nor oversold (below 30) | 57.9 |
|---|---|---|
| Position in its 14-day range | it is trading in the upper half of its 14-day range ($109.23 to $127.50) — its "stochastic" reading is 61 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been slipping within that range over the last few sessions. | 60.7 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, turned bearish about 3 trading days ago (its momentum flipped negative) | 3 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $127.99 | $127.99 |
|---|---|---|
| From the 52-week high | it is 6.0% below its 52-week high (its highest price of the past year) | -6.0% |
| Above the 52-week low | it is 29.7% above its 52-week low (its lowest price of the past year) | +29.7% |
| Below the 52-week high | it is 6.0% below its highest point of the past year | 6.0% |
| Since a 20-day breakout | it made a new 20-day high about 10 trading days ago | 10 sessions |
| Since a 55-day breakout | it made a new 55-day high about 10 trading days ago | 10 sessions |
| All-time high | its highest closing price on record is $127.99 (set on 2025-10-24) | $127.99 |
| Given back of the 52-week move | over the past year its closes ranged ($93.83 to $127.18), and it has recovered well over two thirds of its fall from last year’s high — 79% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $114.44 to $115.51. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 79.4% |
| From the all-time high | it is 6.0% below its all-time high | -6.0% |
| Nearest price level | it is trading 1.8% below a resistance level at $122.51 — a price it turned at four times since 2025-05-20, most recently on 2025-07-01. Since 2024-08-21 it has 8 such levels below the current price and 3 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | +1.8% |
| All-time low | its lowest closing price on record is $0.03978 (set on 2003-04-09) | $0.03978 |
| Above the all-time low | it is 302361.2% above its all-time low | +302,361% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are unusually wide versus its own recent history (wider than about 84% of the past ~6 months) | 84th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $3.11 between its high and its low — about 2.6% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $3.11 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $107.69 and $130.28 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $107.69 – $118.99 – $130.28 |
| Typical daily range (% of price) | its price moves about 2.6% in a typical session — calmer than most companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 2.6% |
| Stretch from the 200-day average | it is trading 4.2 daily ranges above its 200-day average price (12.2% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 4.2 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 0.73× |
|---|
Analyst
2
| Change in the average price target | analysts have raised their average price target by 0.9% since the prior reading | +0.8% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
2
| Since a doji | 1 session ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 1 session ago |
|---|---|---|
| Since a bearish engulfing | 6 sessions ago it opened above the previous session's close and finished below that session's open — a "bearish engulfing" pair, where one down day more than undid the up day before it | 6 sessions ago |
Price gaps
3
| Gap at the open | it opened on 2026-08-21 at essentially the same price it closed at the session before — no meaningful overnight gap | +0.0% |
|---|---|---|
| Open gap | it gapped 12.5% above the previous close 11 sessions ago and has not traded back through the level it left behind at 110.9 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | +12.5% |
| Gap filled | a 3.6% gap up opened on 2026-07-24 has been "filled" 16 sessions ago — price traded back through the level the gap left behind, and it took 4 sessions to close | 16 sessions ago |
Price streaks
1
| Closing streak | it has closed lower 3 sessions in a row, a -1.47% move over the run — an unbroken run of down days, which describes what has already happened and says nothing about the next session | 3 sessions down |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock beat the market by 5.0 percentage points (the stock gained 7.3% while the market gained 2.3%) | +5.0% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 12.1 percentage points (the stock gained 15.2% while the market gained 3.1%) | +12.1% |
| vs market, 6 months | over the past 6 months this stock beat the market by 1.8 percentage points (the stock gained 12.9% while the market gained 11.1%) | +1.9% |
| vs market, 12 months | over the past 12 months this stock lagged the market by 23.0 percentage points (the stock lost 2.5% while the market gained 20.5%) | -23.0% |
Signal agreement
2
| Bullish technical signals | 5 of the 9 technical signals we can compute for it are currently in a bullish state: a strong uptrend, with buyers in control, a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average, outperforming the market over 6 months, trading above the Ichimoku cloud — these describe past price behaviour, not a forecast | 5 of 9 |
|---|---|---|
| Bearish technical signals | 1 of the 9 technical signals we can compute for it is currently in a bearish state: MACD momentum is negative — these describe past price behaviour, not a forecast | 1 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 13% above the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-16 and projected forward over today's price, the side traders read as an established uptrend, with the band below acting as the level that would have to give way. The band itself is thin, spanning 1.8% of the share price, which is taken to mean a barrier that gives way easily. | +12.7% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 14% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $105.84 — a volume-weighted average of daily closes over 156 sessions, not a true tick-by-tick VWAP. | +13.7% |
|---|---|---|
| Vs the average paid since it last reported | the price is 2% below the average price paid since it last reported on 2026-08-05 (its 8-K), so the typical buyer over that stretch is under water. That average is $122.51 — a volume-weighted average of daily closes over 13 sessions, not a true tick-by-tick VWAP. | -1.8% |
Price levels it has turned at before
EHC last closed at $120.31 on 2026-08-21. Since 2024-08-21 it has turned at 8 prices below its last close and 3 above; the 3 nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $122.51 | Resistance | 1.8% above the last close | turned there four times · 2025-05-20 to 2025-07-01 |
| $117.02 | Support | 2.7% below the last close | turned there six times · 2025-05-23 to 2026-07-28 |
| $125.25 | Resistance | 4.1% above the last close | turned there twice · 2025-08-21 to 2025-10-09 |
| $127.63 | Resistance | 6.1% above the last close | turned there four times · 2025-09-12 to 2026-08-11 |
| $109.51 | Support | 9.0% below the last close | turned there 7 times · 2025-11-19 to 2026-07-31 |
| $106.36 | Support | 11.6% below the last close | turned there 7 times · 2025-07-16 to 2026-07-14 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a three-part upward correction — the A-B-C shape chartists use for a pullback — now complete.
This labelling fails — stops being a possible reading at all — if it closes above $127.50.
This is one of several labellings that fit the same swings, so treat it as a reading rather than the reading. It was chosen from 2 labellings that survived the rules, counting shorter readings of the same bars.
Alternate reading: The same swings also read as a five-part sequence in leg 4, which fails on a close below $117.17.
This reading has stood for 4 trading days, since 2026-08-18.
Read from daily closes as of 2026-08-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · Recent golden cross (50-day crossed above 200-day) · Tested and reclaimed 200-day support · MACD just crossed bearish (12/26/9) · in a strong, established uptrend (ADX) · Under water since its last earnings report (below the anchored VWAP) | Learn: moving average · golden cross · adx · rsi · macd · breakout
Based on daily closing prices as of 2026-08-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingStrong Buy (1.08 mean, 1=Strong Buy…5=Strong Sell) — 12 analysts
- Mean price target$148.17 range $140.00 – $155.00; median $150.00
Analyst estimates, as of 2026-08-19. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for EHC
- Consensus EPS estimate$1.36 next reporting period, as of 2026-08-19
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["High concentration of revenue derived from Medicare and sensitivity to changes in government reimbursement policies.","Risk of audit-related payment denials, recoupments, and increased regulatory compliance costs.","Competitive pressures from Medicare Advantage payors and potential shifts in site-of-care preferences."]
What changed in the latest 10-Q
AI-assisted comparison of EHC's 10-Q filed 2026-05-01 against the prior one filed 2025-10-31.
Management's Discussion & Analysis (MD&A)
- Added:
- Newer filing references 2025 Form 10-K filed February 26, 2026 (vs. older filing referencing 2024 Form 10-K filed February 28, 2025)
- Newer filing states 174 IRFs operated as of March 31, 2026 (vs. older filing stating 170 IRFs as of September 30, 2025)
- Newer filing reports 9.0% net operating revenue increase for three months ended March 31, 2026 (vs. older filing reporting 9.4% for three months and 10.6% for nine months ended September 30, 2025)
- Newer filing describes operations begun in Irmo, South Carolina in March 2026 with 49 beds
- Newer filing states 44 new beds added to existing hospitals in first quarter 2026
- Newer filing's development table removes projects previously listed as 2025 openings (St. Petersburg, Amarillo, Lake Worth) and removes 2027 projects (North Las Vegas, Palm Beach Gardens)
- Newer filing lists Fishers, Indiana and Cookeville, Tennessee as 2027 projects not in older filing
- Newer filing's development table shows 150-200 other bed additions for 2026-2027 (vs. older filing showing ~127 for 2025 and 150-200 for 2026-2027)
- Newer filing references Part II, Item 7 for Key Challenges (vs. older filing referencing Part II, Item 7 but text cut off)
- Removed:
- Older filing's specific Medicare enrollment projection of 'approximately 71 million people over the age of 65 by 2030' removed in newer filing
- Older filing's reference to 'de novo hospitals' in growth discussion changed to 'new hospitals' in newer filing
- Reworded:
- Reference changed from '2024 Form 10-K' to '2025 Form 10-K' throughout
- Reference changed from 'Part II, Item 7' location to 'Part I, Item 1, Business' for competitive strengths in newer filing
- Phrase changed from 'de novo hospitals and bed additions' to 'new hospitals and bed additions'
- Demographic language streamlined: removed specific Medicare enrollment projection and simplified growth statement in newer filing
- Notes:
- Older filing text appears truncated at end of Key Challenges section; comparison is complete up to available text
- Comparison reflects filings for different fiscal periods (Q1 2026 vs. Q3 2025), making some operational metric differences expected rather than indicating accounting changes
Risk Factors
- Added:
- Newer filing references 2025 Annual Report on Form 10-K (year ended December 31, 2025) vs. older filing referencing 2024 Annual Report (year ended December 31, 2024)
- Added bullet point: 'Changes in our payor mix, including shifts to Medicare Advantage providers that limit patient access to inpatient rehabilitation, or the acuity of our patients could reduce our volumes, revenues or profitability.'
- Added to payment reforms bullet: 'value-based episodic payment models' as a specific reform example
- Page number changed from 35 to 31 for Item 1A Risk Factors
- Removed:
- Removed phrase 'or profitability' from older 'Changes in our payor mix' bullet (consolidated into expanded version)
- Removed incomplete text at end of older filing regarding 'de novo developments' integration language
- Reworded:
- Older bullet 'Changes in our payor mix or the acuity of our patients could reduce our revenues or profitability' expanded to: 'Changes in our payor mix, including shifts to Medicare Advance providers that limit patient access to inpatient rehabilitation, or the acuity of our patients could reduce our volumes, revenues or profitability' (newer filing adds 'volumes' and specifies Medicare Advantage detail)
- Older bullet 'Our inability to maintain proper local, state and federal licensing...could decrease our revenues' changed to include comma after 'participation' in newer filing
- Older bullet about information systems changed from 'and governmental mandates' to ', and governmental mandates' (punctuation change)
- Notes:
- Older filing text is truncated at the end of the last bullet point; comparison limited to complete text available
- Page number changes reflect formatting differences but do not indicate content changes
- Both filings are incomplete 10-Q sections; full Risk Factors section not fully provided in either source
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
No open-market insider purchases or sales recorded in the last 90 days.
- Last 180 days0 buys · 3 sells ($3M) — 2 selling insiders
Most recent open-market transaction: 2026-05-15. As of 2026-08-24.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about EHC's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Congressional trading disclosures
U.S. House members publicly disclose their own, their spouse's, and dependent children's stock transactions under the STOCK Act. We hold 4 matched disclosures for EHC from U.S. House Clerk Periodic Transaction Report filings.
Congressional trading disclosures →Institutional ownership (13F)
6 institutional 13F filers reported holding EHC as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 6
- Reported shares held 14,909,245
- Reported value $1,442,171,174
reported quarterly holdings change (2025-12-31 → 2026-03-31): 0 new, 5 increased, 1 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
EHC had 3,653,920 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
EHC had 3.70% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 4.89 days to cover at the same settlement.
- Reported short interest (shares) 3,653,920
- Short interest (% of shares outstanding) 3.70%
- Prior settlement (shares) 3,917,662
- Reported change -6.73%
- Days to cover (reported) 4.89
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Kindred Healthcare
- Select Medical (SEM)
- HCA Healthcare (HCA)
- Community Health Systems (CYH)
- Universal Health Services (UHS)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare EHC vs…
Frequently asked questions
What does Encompass Health (EHC) do?
Encompass Health is the largest owner and operator of inpatient rehabilitation hospitals in the United States, providing specialized rehabilitative treatment for patients recovering from major injuries or illnesses, such as strokes and hip fractures. The company utilizes interdisciplinary clinical teams to deliver intensive, facility-based therapy aimed at restoring patient functional ability and independence.
What sector is Encompass Health (EHC) in?
Encompass Health (EHC) is classified in the Health Care sector. Its industry is inpatient rehabilitation services. It trades on NYSE.
Does EHC pay a dividend?
Yes — Encompass Health (EHC) pays a dividend, with an indicated yield of about 0.91% and 3-year non-decreasing per-share dividend streak (SEC EDGAR XBRL) (market data, as of 2026-08-24). Informational only — not financial advice.
Who are Encompass Health's (EHC) competitors?
Notable peers of Encompass Health (EHC) include Kindred Healthcare, Select Medical, HCA Healthcare, Community Health Systems and Universal Health Services. This peer set is informational only — not financial advice.
Has there been recent Congressional stock trading in EHC?
Yes — we hold 4 matched STOCK Act disclosures for EHC from U.S. House Clerk Periodic Transaction Report filings. These are legally-required disclosures (often filed 30–45 days after the trade), may belong to a U.S. House member, their spouse, or a dependent child, and are not an indicator of company performance or investment advice.
Is Encompass Health (EHC) overbought or oversold right now?
Encompass Health (EHC) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 58, in the neutral middle (as of 2026-08-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on EHC come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.